Alvotech trades on the Nasdaq Stock Market

"Day we will never forget" - Video

Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide today announced that its ordinary shares and warrants will begin trading on theNasdaq Stock Market LLC(“Nasdaq”) on June 16, under the new ticker symbols “ALVO” and “ALVOW”, respectively. This follows the successful completion of the company’s business combination with Oaktree Acquisition Corp. II (“OACB”), a special purpose acquisition company sponsored by an affiliate of Oaktree Capital Management, L.P.(“Oaktree”). The merger, which was approved onJune 7by OACB shareholders, creates a publicly traded, pureplay company focused on the growing global biosimilar market.

Becoming a public company is a historic milestone on Alvotech’s growth journey.

Róbert Wessman, founder and executive Chairman of Alvotech